Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : NOVN save search
Novan Reports First Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-05-11 (Crawled : 23:00) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 895.67%
H: 5.22%
C: -3.48%
financial results results
Novan’s NITRICIL™ Technology Shows In Vitro Antiviral Effect Against SARS-CoV-2 in Human Airway Infection Model
Published: 2020-10-14 (Crawled : 22:13) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 61.52%
H: 0.94%
C: -23.15%
antiviral injection xin sars-cov-2 infections in vitro
Novan Reports Positive Topline Results from Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
Published: 2021-06-11 (Crawled : 11:00) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 58.85%
H: 30.08%
C: 2.23%
molluscum positive results topline phase 3 trial
Novan Acquires EPI Health, a Specialty Dermatology Company
Published: 2022-03-11 (Crawled : 12:00) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 15.43%
H: 0.0%
C: 0.0%
health derm
Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology
Published: 2021-04-22 (Crawled : 13:00) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 11.8%
H: 8.87%
C: 3.97%
Novan Satisfies $16.5 Million Outstanding Promissory Note
Published: 2022-07-19 (Crawled : 13:00) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 11.52%
H: 0.0%
C: -4.8%
Novan Engages Catalent to Develop Intranasal Formulation of Berdazimer Sodium for COVID-19 Program
Published: 2020-12-21 (Crawled : 14:03) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 10.22%
H: 0.53%
C: -10.19%
covid covid-19 program
Novan Anticipates Current Cash Position Provides Sufficient Capital to Conduct Additional SB206 Phase 3 Pivotal Trial
Published: 2020-06-25 (Crawled : 22:13) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 8.88%
H: 1.33%
C: -14.96%
phase 3 trial positive
Novan Provides Pipeline and Priority Development Programs Update
Published: 2020-09-14 (Crawled : 22:13) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 8.3%
H: 11.76%
C: 4.33%
program
Novan Reports Full Year 2022 Financial Results and Provides Corporate Update
Published: 2023-03-30 (Crawled : 11:00) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 7.21%
H: 7.55%
C: 0.84%
year update financial results
Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement
Published: 2020-04-03 (Crawled : 22:13) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 6.82%
H: 1.06%
C: -17.64%
fda program
Novan Receives Approval to Transfer to Nasdaq Capital Market
Published: 2020-11-04 (Crawled : 22:13) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 5.93%
H: 1.54%
C: -6.48%
approval market nasdaq
FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024
Published: 2023-03-07 (Crawled : 13:20) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 5.3%
H: 1.44%
C: -2.88%
molluscum treatment fda pdufa
Novan Announces Late-Breaking Abstract Accepted for Presentation at American Academy of Dermatology’s (AAD) 2022 Annual Meeting
Published: 2022-03-24 (Crawled : 13:30) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 4.99%
H: 0.26%
C: -4.75%
presentation
FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024
Published: 2023-03-08 (Crawled : 03:00) - novan.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 4.44%
H: 0.0%
C: -4.26%
molluscum treatment fda pdufa
Novan Moves Forward with Unified Corporate Branding
Published: 2023-03-08 (Crawled : 14:00) - novan.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 4.44%
H: 0.0%
C: -4.26%
Novan to Host Live Audio Webcast of 2020 Annual Meeting of Stockholders
Published: 2020-07-23 (Crawled : 22:13) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 4.41%
H: 1.15%
C: -8.45%
audio
Novan Completes Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
Published: 2021-02-01 (Crawled : 13:06) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 4.39%
H: 5.88%
C: 1.68%
treatment phase 3 enroll
Novan Initiates B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
Published: 2020-08-31 (Crawled : 22:13) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 4.23%
H: 2.02%
C: -10.44%
phase 3 treatment
Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
Published: 2022-12-01 (Crawled : 14:00) - novan.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 4.21%
H: 19.68%
C: 15.15%
conference medical aesthetic
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
TIRX | $1.13 133.09% 44M
|
AGBA | $0.8978 124.45% 60M
|
Finance
BPTH | $6.18 90.74% 39M
|
Health Technology
INVO | $1.44 89.47% 3M
|
Health Technology
SINT | $0.0588 57.64% 240M
|
Health Technology
XPON | $2.66 37.82% 5.2M
|
THCH | $1.38 32.69% 9.9M
|
n/a
ALRN | $5.605 31.88% 210K
|
Health Technology
HOLO | $2.92 30.36% 22M
|
VTNR S | $1.25 27.66% 3.2M
|
Industrial Services
Your saved searches
Save your searches and get alerts when important news are released.